title: Antinociceptive interaction between opioids and medetomidine: systemic additivity and spinal synergy.
abstract: The antinociceptive interaction on the tail flick (TF) and hot plate (HP) tests between opioid analgesics and medetomidine after intravenous (iv) or intrathecal administration were examined by isobolographic analysis. Male Sprague-Dawley rats received fixed ratios of medetomidine to morphine, fentanyl, and meperidine of 1:10 and 1:30, 10:1, and 1:3, respectively, by iv administration or 10:1, 3:1 and 10:1, and 1:3 by intrathecal administration, respectively. Data were expressed as the percentage maximal possible effect (%MPE). The A50 (dose producing 50% MPE) for each drug or drug combination was determined from the dose-response curve. Isobolographic analysis revealed that the effect of medetomidine combined with fentanyl, morphine, or meperidine was additive after iv administration. The intrathecal administration of combinations of medetomidine with the opioids produced a synergistic antinociceptive effect in the TF but not HP test. These data confirmed that the interaction between medetomidine and opioids in producing antinociception may be additive or synergistic, depending on the route of administration, drug ratio administered, and level of processing of the nociceptive input (i.e., spinal vs. supraspinal). Moreover, these results were consistent with a spinal role for alpha-2 adrenoceptors in mediating antinociception. The authors suggest that the interaction between the opioid and alpha-2 adrenergic receptors occurs within the spinal cord.
authors.affiliation: Anaquest, Division of BOC Health Care, Murray Hill, New Jersey 07974.
authors.forename: M H
authors.initials: MH
authors.lastname: Ossipov
authors.forename: S
authors.initials: S
authors.lastname: Harris
authors.forename: P
authors.initials: P
authors.lastname: Lloyd
authors.forename: E
authors.initials: E
authors.lastname: Messineo
authors.forename: B S
authors.initials: BS
authors.lastname: Lin
authors.forename: J
authors.initials: J
authors.lastname: Bagley
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D004347:Drug Interactions; D004357:Drug Synergism; D005283:Fentanyl / Q000008:administration & dosage / Q000627:therapeutic use; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D020926:Medetomidine; D008614:Meperidine / Q000008:administration & dosage / Q000627:therapeutic use; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000316:Adrenergic alpha-Agonists; D000701:Analgesics, Opioid; D007093:Imidazoles; D009020:Morphine; D008614:Meperidine; D020926:Medetomidine; D005283:Fentanyl